Middle East Tensions Threaten India's Global Pharmacy Role, Squeezing Pharmaceutical Supply Chains

NEW DELHI – Escalating geopolitical tensions across the Middle East, particularly disruptions in vital maritime corridors, are casting a long shadow over India's pharmaceutical industry, threatening to inflate drug prices, cause shipment delays, and potentially lead to medicine shortages worldwide. As a critical supplier of affordable generic medicines, India's pharmaceutical sector faces mounting pressure from surging freight costs, extended transit times, and increasing raw material prices, compelling both the government and industry to seek urgent mitigation strategies.

The current instability, marked by Houthi attacks in the Red Sea and broader regional conflicts involving significant global powers, has fundamentally altered traditional trade routes, forcing a re-evaluation of global supply chain resilience. For India, a nation intricately linked to these routes for both its pharmaceutical exports and critical imports, the disruptions pose a significant challenge to its status as the "pharmacy of the world."

The Geopolitical Vortex and Strained Trade Arteries

The primary catalyst for the current supply chain woes is the persistent geopolitical unrest in the Middle East, which has rendered key shipping lanes treacherous. The Red Sea-Suez Canal corridor, a crucial artery connecting Asia with Europe, North Africa, and parts of the United States, has seen numerous commercial vessels targeted, prompting a widespread rerouting of maritime traffic. Similarly, disruptions to tanker movement through the Strait of Hormuz are impacting petrochemical supplies essential for drug manufacturing.

Shipping companies are increasingly circumventing the Red Sea by diverting vessels around the Cape of Good Hope, a much longer journey that adds an estimated 10 to 20 days to transit times. This extended travel period translates directly into significantly higher logistics costs. Freight charges have reportedly doubled on some routes, with additional surcharges ranging from $4,000 to $8,000 per shipment. Overall, freight costs have increased by 40-50% on certain India-Europe and India-US routes. Compounding these expenses are skyrocketing war-risk insurance premiums, which have seen increases of over a thousand-fold in some instances.

Beyond sea freight, air cargo routes have also been affected. Airspace closures in Gulf countries can necessitate rerouting, leading to longer transit times and increased costs, particularly for urgent and high-value pharmaceutical consignments such as oncology medicines, clinical trial materials, and certain active pharmaceutical ingredients (APIs).

A Dual Impact: Export Challenges and Import Dependencies

India's pharmaceutical industry finds itself grappling with a dual challenge: safeguarding its extensive export market while securing essential raw material imports. The Middle East itself is a significant destination for Indian generic medicines, with countries like the UAE, Saudi Arabia, and Iraq being major importers. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has warned that disruptions could lead to a potential loss of $300 million to $600 million (₹2,500 to ₹5,000 crore) in pharmaceutical exports. March 2026 data already reflects a sharp decline in India's pharmaceutical exports, reaching a five-year low due to the conflict.

A substantial portion of India's pharmaceutical exports, including finished dosage forms, biosimilars, and vaccines, are destined for Europe, North Africa, and the US East Coast via the Red Sea-Suez Canal maritime corridor. Any delays or disruptions along this route directly threaten the timely delivery of temperature-sensitive products, such as vaccines and biologics, which require stringent cold chain management to maintain efficacy and shelf-life.

Concurrently, India's pharmaceutical manufacturing heavily relies on imported raw materials. Active Pharmaceutical Ingredients (APIs), intermediates, and petrochemical-based packaging materials are crucial inputs, with China accounting for a dominant share—approximately 73.7% of India's API imports in FY2024-25. Disruptions in the supply of these materials, coupled with rising oil and petrochemical prices, directly impact production costs for Indian manufacturers.

Soaring Costs and the Specter of Shortages

The cumulative effect of increased freight, insurance, and raw material costs is putting immense pressure on manufacturers' margins. Prices for key APIs and chemicals have reportedly surged by 40-100%, with some instances seeing increases of up to 200-300%. The cost of paracetamol inputs, for example, nearly doubled in a matter of days. Packaging materials like aluminum, plastic, and glass are also becoming more expensive.

For generic drug manufacturers, who often operate on thin margins and adhere to fixed pricing under long-term tender contracts, these cost escalations are particularly challenging. Smaller and medium-sized manufacturers are feeling the most strain, with some reportedly considering cutting output. This situation raises concerns about potential medicine shortages and price hikes for a wide range of essential medications, including common painkillers, antibiotics, antipyretics, and drugs for diabetes and heart conditions, especially affecting low-cost generics.

While some companies have increased inventory levels in FY2024 to buffer against supply shocks, the clock is ticking for buffer stocks that may last only three to six months.

India's Proactive Response to Build Resilience

In response to these formidable challenges, the Indian government and pharmaceutical industry are implementing a multi-pronged strategy to enhance supply chain resilience and mitigate the impact of geopolitical instability. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has strongly advised exporters to diversify their shipping routes and explore alternative logistics options to ensure stability. Pharmexcil is also advocating for government support through freight relief measures, such as subsidies or logistical assistance, and sustained dialogue with international regulatory bodies.

The government has launched a comprehensive audit of critical supply chains across various sectors, including pharmaceuticals, to identify vulnerabilities and reduce import dependence. Initiatives like the Production Linked Incentive (PLI) Scheme and the establishment of Bulk Drug Parks aim to boost domestic manufacturing of APIs and Key Starting Materials (KSMs), thereby reducing reliance on imports. Customs and tax reforms are also being pursued to foster a more competitive domestic manufacturing environment. As a direct response to the current crisis, the government has temporarily waived an 8.25% customs duty on 40 critical raw materials used in drug manufacturing, effective from April 2 to June 30, 2026. Furthermore, a "RELIEF" package was introduced in March to aid exporters facing higher freight, insurance, and war-related risks.

The Commerce Secretary has voiced confidence in the industry's adaptability, underscoring the government's commitment to minimizing supply chain disruptions. Industry players are also adopting strategies such as multi-sourcing, local sourcing, backward integration, and optimizing inventory management. Some manufacturers are preemptively increasing their inventory in destination markets to safeguard against delays. Alternative maritime routes, including those around Africa via the Cape of Good Hope, are being actively utilized, and there are cautious signs of a gradual resumption of shipments through the Red Sea route, signaling a potential, albeit slow, recovery.

Despite these efforts, the situation remains fluid. The ongoing tensions in the Middle East underscore the interconnectedness of global supply chains and the profound impact geopolitical events can have on the accessibility and affordability of essential medicines worldwide. India's ability to navigate these challenges will not only determine the health of its own pharmaceutical sector but also its continued role in global public health.